Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gabitril in Generalized Anxiety Disorder
NCT00236054Phase 3Completed
- Sponsor
- Cephalon, Inc.
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in generalized anxiety disorder (GAD) comparing Gabitril with Placebo (2 arms). Primary endpoint: Hamilton Rating Scale for Anxiety at 10 weeks. Started Oct 2004; status: completed.
02
Drugs
tiagabine
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT00236054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00236054.